Taselisib-Femara Combo Improves Response in Certain Postmenopausal Women with Early Breast Cancer, Study Shows

Taselisib-Femara Combo Improves Response in Certain Postmenopausal Women with Early Breast Cancer, Study Shows
Adding  taselisib to Femara (letrozole) increases the measurable response in certain postmenopausal women with early breast cancer, according to a new study. The benefits were also seen in women whose tumors had mutations in the PIK3CA gene, researchers reported in a press release. The findings were recently presented at the European Society for Medical Oncology (ESMO) 2017 Congress, with the title "Primary results of LORELEI: a phase II randomized, double-blind study of neoadjuvant letrozole (LET) plus taselisib versus LET plus placebo (PLA) in postmenopausal patients (pts) with ER+/HER2-negative early breast cancer (EBC)." They were based on data from the recently completed Phase 2 LORELEI study (NCT02273973). Taselisib, an PI3K inhibitor developed by Roche, works by blocking a protein called PI3K (short for phosphoinositide 3-kinase), which helps cancer cells grow. LORELEI, a randomized, double-blind
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.